LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

Начало・Списък с акции・Schrodinger Inc

Schrodinger Inc

Затворен

СекторЗдравеопазване

11.25 0.36

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

11.13

Максимум

11.51

Ключови измерители
By Trading Economics
Приходи	10M -33M
Продажби	-435K 54M
Марж на печалбата	-60.369
Служители	891
EBITDA	10M -31M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+96.08% upside

Дивиденти
By Dow Jones
Следващи печалби	25.02.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-686M 827M
Предишно отваряне	10.89
Предишно затваряне	11.25

Настроения в новините

By Acuity

67%

33%

317 / 351 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

23.27 / 26.13 Подкрепа & съпротива

Schrodinger Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

24.02.2026 г., 23:07 ч. UTC

Печалби

Woolworths 1st Half Profit Hit By Worker Pay Dispute, Still Boosts Dividend

24.02.2026 г., 23:01 ч. UTC

Печалби

Fortescue 1st Half Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

24.02.2026 г., 22:59 ч. UTC

Печалби

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability -- Update

24.02.2026 г., 22:42 ч. UTC

Печалби

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability

24.02.2026 г., 22:24 ч. UTC

Придобивния, сливания и поглъщания

Warner Bros. Discovery Board Says Paramount Skydance's New Proposal Could Top Netflix Agreement -- Update

24.02.2026 г., 23:46 ч. UTC

Пазарно говорене

Gold Edges Higher Amid Possible Position Adjustments -- Market Talk

24.02.2026 г., 23:36 ч. UTC

Пазарно говорене

Nikkei May Rise, Tracking Wall Street's Rebound -- Market Talk

24.02.2026 г., 23:30 ч. UTC

Пазарно говорене

Fortescue's Copper Bet Is Long Term, While Iron Ore Remains Near-Term Driver -- Market Talk

24.02.2026 г., 23:20 ч. UTC

Пазарно говорене

Fortescue Dividend Beat Overshadows Profit Miss -- Market Talk

24.02.2026 г., 23:20 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

24.02.2026 г., 23:16 ч. UTC

Печалби

Oversea-Chinese Banking Corp.'s CEO: "Looking Ahead, We Remain Cautious Yet Positive">O39.SG

24.02.2026 г., 23:13 ч. UTC

Печалби

Oversea-Chinese Banking Corp. FY25 Non-Interest Income S$5.46B Vs. S$4.72B >O39.SG

24.02.2026 г., 23:12 ч. UTC

Печалби

Oversea-Chinese Banking Corp.: FY25 Net Interest Income S$9.15B Vs. S$9.76B>O39.SG

24.02.2026 г., 23:10 ч. UTC

Печалби

Oversea-Chinese Banking Corp. FY25 NPL Ratio 0.9%, Unchanged on Year>O39.SG

24.02.2026 г., 23:10 ч. UTC

Печалби

Oversea-Chinese Banking Corp. FY25 Net Interest Margin 1.91%, Down 29bps on Year>O39.SG

24.02.2026 г., 23:08 ч. UTC

Печалби

Oversea-Chinese Banking Corp. FY25 Net S$7.42B Vs. Net S$7.59B >O39.SG

24.02.2026 г., 23:07 ч. UTC

Печалби

Oversea-Chinese Banking Corp. FY25 Total Income S$14.61B Vs. S$14.47B>O39.SG

24.02.2026 г., 22:52 ч. UTC

Печалби

Woolworths 1H Profit Hit By Worker Pay Dispute, Still Boosts Dividend

24.02.2026 г., 22:46 ч. UTC

Печалби

Fortescue 1H Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

24.02.2026 г., 22:31 ч. UTC

Придобивния, сливания и поглъщания

Warner Receives New Bid From Paramount -- 3rd Update

24.02.2026 г., 22:29 ч. UTC

Печалби

Woolworths: FY Ebit Growth for Australian Food Expected at Upper End of Mid-to-High Single Digit Range Provided in August

24.02.2026 г., 22:28 ч. UTC

Печалби

Woolworths: Australian Food Current Growth Rates Reflect Some Benefit from Cycling of Industrial Action Impacts

24.02.2026 г., 22:27 ч. UTC

Печалби

Woolworths: Australian Food Sales +7.2% Excluding Tobacco in 2H First Seven Weeks

24.02.2026 г., 22:27 ч. UTC

Печалби

Woolworths: Australian Food Sales +5.8% in 2H First Seven Weeks

24.02.2026 г., 22:25 ч. UTC

Печалби

Woolworths: Customers Continue to be Value-Focused, Shopping Multiple Retailers in Highly Competitive Environment

24.02.2026 г., 22:24 ч. UTC

Печалби

Woolworths: Trading in 3Q to Date Has Been Strong in Australian Food

24.02.2026 г., 22:23 ч. UTC

Печалби

Woolworths 1H Group Sales A$37.1 Bln, Up 3.4%

24.02.2026 г., 22:22 ч. UTC

Печалби

Woolworths Interim Dividend 45 Australian Cents/Share

24.02.2026 г., 22:22 ч. UTC

Печалби

Woolworths 1H Profit Before Significant Items A$859 Mln, Up 16.4%

24.02.2026 г., 22:21 ч. UTC

Печалби

Woolworths 1H Statutory Net Profit A$374 Mln, Down 49.4%

Сравнение с други в отрасъла

Ценова промяна

Schrodinger Inc Прогноза

Ценова цел

By TipRanks

96.08% нагоре

12-месечна прогноза

Среден 22 USD 96.08%

Висок 25 USD

Нисък 18 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за Schrodinger Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

6 ratings

Купи

Задържане

Продай

Според 6 анализатори, дали борсови рейтинги на Schrodinger Inc през последните 3 месеца.

Техническа оценка

By Trading Central

23.27 / 26.13Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bullish.

Настроение

By Acuity

317 / 351 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Schrodinger Inc

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. It has a research collaboration and license agreement with Novartis AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.